JP7328261B2 - セリンプロテアーゼ阻害剤カザル(spik)組成物および方法 - Google Patents

セリンプロテアーゼ阻害剤カザル(spik)組成物および方法 Download PDF

Info

Publication number
JP7328261B2
JP7328261B2 JP2020570410A JP2020570410A JP7328261B2 JP 7328261 B2 JP7328261 B2 JP 7328261B2 JP 2020570410 A JP2020570410 A JP 2020570410A JP 2020570410 A JP2020570410 A JP 2020570410A JP 7328261 B2 JP7328261 B2 JP 7328261B2
Authority
JP
Japan
Prior art keywords
seq
sequence
spik
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020570410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021515597A (ja
JP2021515597A5 (cg-RX-API-DMAC7.html
Inventor
シュアンヨン ルー,
フェリックス ルー,
Original Assignee
インケア バイオテック, エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インケア バイオテック, エルエルシー filed Critical インケア バイオテック, エルエルシー
Publication of JP2021515597A publication Critical patent/JP2021515597A/ja
Publication of JP2021515597A5 publication Critical patent/JP2021515597A5/ja
Priority to JP2023127022A priority Critical patent/JP7539536B2/ja
Application granted granted Critical
Publication of JP7328261B2 publication Critical patent/JP7328261B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020570410A 2018-03-06 2019-03-06 セリンプロテアーゼ阻害剤カザル(spik)組成物および方法 Active JP7328261B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023127022A JP7539536B2 (ja) 2018-03-06 2023-08-03 セリンプロテアーゼ阻害剤カザル(spik)組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862639345P 2018-03-06 2018-03-06
US62/639,345 2018-03-06
US201862639850P 2018-03-07 2018-03-07
US62/639,850 2018-03-07
PCT/US2019/020999 WO2019173503A2 (en) 2018-03-06 2019-03-06 Serine protease inhibitor kazal (spik) compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023127022A Division JP7539536B2 (ja) 2018-03-06 2023-08-03 セリンプロテアーゼ阻害剤カザル(spik)組成物および方法

Publications (3)

Publication Number Publication Date
JP2021515597A JP2021515597A (ja) 2021-06-24
JP2021515597A5 JP2021515597A5 (cg-RX-API-DMAC7.html) 2022-03-15
JP7328261B2 true JP7328261B2 (ja) 2023-08-16

Family

ID=65818672

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020570410A Active JP7328261B2 (ja) 2018-03-06 2019-03-06 セリンプロテアーゼ阻害剤カザル(spik)組成物および方法
JP2023127022A Active JP7539536B2 (ja) 2018-03-06 2023-08-03 セリンプロテアーゼ阻害剤カザル(spik)組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023127022A Active JP7539536B2 (ja) 2018-03-06 2023-08-03 セリンプロテアーゼ阻害剤カザル(spik)組成物および方法

Country Status (6)

Country Link
US (2) US12180301B2 (cg-RX-API-DMAC7.html)
EP (1) EP3762426A2 (cg-RX-API-DMAC7.html)
JP (2) JP7328261B2 (cg-RX-API-DMAC7.html)
CN (2) CN120005029A (cg-RX-API-DMAC7.html)
CA (1) CA3093295A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019173503A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120005029A (zh) 2018-03-06 2025-05-16 英凯尔生物科技有限责任公司 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法
JP7658946B2 (ja) * 2019-07-08 2025-04-08 インケア バイオテック, エルエルシー カザール型抗セリンプロテアーゼ阻害因子(spik)抗体、免疫複合体、及び使用方法
KR20220080098A (ko) 2019-09-11 2022-06-14 아임케어 바이오테크, 엘엘씨. 항-세린 프로테아제 억제제 카잘(spik) 항체의 에피토프
EP4211468A4 (en) 2020-09-11 2024-10-09 Glympse Bio, Inc. DETECTION OF EX VIVO PROTEASE ACTIVITY FOR DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT OF DISEASES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140308657A1 (en) 2010-12-09 2014-10-16 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine Serine protease inhibitor kazal antibodies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0731106B1 (en) 1993-10-01 2004-11-17 Teikoku Hormone Mfg. Co., Ltd. Dolastatin derivatives
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20050123536A1 (en) 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
CA2494104A1 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US8193328B2 (en) 2005-09-08 2012-06-05 Philadelphia Health & Education Corporation Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
CN101970498A (zh) 2007-10-25 2011-02-09 维文蒂阿生物技术公司 针对变体HnRNPG的癌相关表位的抗体及其应用
PE20120877A1 (es) 2009-04-01 2012-08-06 Genentech Inc ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
US20110206697A1 (en) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Spink1 targeted therapy
US9206257B2 (en) 2011-04-19 2015-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
CN104994875B (zh) 2013-02-15 2018-10-09 免疫医疗公司 嵌合和人源化抗组蛋白抗体
US10746742B2 (en) 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
AU2017239637A1 (en) 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
EP4219559A3 (en) * 2017-12-22 2023-10-18 Jounce Therapeutics, Inc. Antibodies for lilrb2
CN120005029A (zh) 2018-03-06 2025-05-16 英凯尔生物科技有限责任公司 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法
CN109678950B (zh) 2019-01-08 2022-05-10 灏灵赛奥(天津)生物科技有限公司 spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品
CN109776679B (zh) * 2019-01-08 2022-06-17 灏灵赛奥(天津)生物科技有限公司 一种丝氨酸蛋白酶抑制因子spink1的抗体、其制备方法和应用
JP7658946B2 (ja) 2019-07-08 2025-04-08 インケア バイオテック, エルエルシー カザール型抗セリンプロテアーゼ阻害因子(spik)抗体、免疫複合体、及び使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140308657A1 (en) 2010-12-09 2014-10-16 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine Serine protease inhibitor kazal antibodies

Also Published As

Publication number Publication date
CA3093295A1 (en) 2019-09-12
CN120005029A (zh) 2025-05-16
US20210253734A1 (en) 2021-08-19
EP3762426A2 (en) 2021-01-13
JP2021515597A (ja) 2021-06-24
CN112292401A (zh) 2021-01-29
JP7539536B2 (ja) 2024-08-23
JP2023166377A (ja) 2023-11-21
WO2019173503A2 (en) 2019-09-12
US20250353927A1 (en) 2025-11-20
US12180301B2 (en) 2024-12-31
WO2019173503A3 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
JP7539536B2 (ja) セリンプロテアーゼ阻害剤カザル(spik)組成物および方法
JP5797687B2 (ja) モノクローナルヒト腫瘍特異的抗体
CN106661110B (zh) 抗muc1抗体或其抗原结合片段及其用途
CN101631802B (zh) 在体内具有抗肿瘤活性的抗人Dlk-1抗体
US20030096285A1 (en) Identifying anti-tumor targets or agents by lipid raft immunization and proteomics
US12377162B2 (en) Anti-serine protease inhibitor kazal (SPIK) antibodies, immunoconjugates, and methods of use
TW200823293A (en) Novel anti-Notch3 antibodies and their use in the detection and diagnosis of disease
AU2022263503B2 (en) Compositions and methods for detecting and treating gastric cancer
EP3954999B1 (en) Compositions and methods for detecting and treating ovarian cancer
US10809263B2 (en) Antigenic composition for detecting auto-antibody with specific response to exosomal protein EIF3A, and method for diagnosing liver cancer using antigenic composition
BR112018013272A2 (en) compositions and methods for detecting and treating esophageal cancer
JP6977105B2 (ja) Igf−1r抗体および癌の診断のためのその使用
JP2026012693A (ja) 抗セリンプロテアーゼインヒビターkazal(spik)抗体のエピトープ
WO2012063839A1 (ja) 抗1本鎖iv型コラーゲンポリペプチド抗体、並びに該抗体を含む医薬、及び腫瘍の診断薬、予防薬、又は治療薬
JP2025082818A (ja) 遺伝子組換え抗体、それを含むキット、およびがん診断におけるその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220307

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230428

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230704

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230803

R150 Certificate of patent or registration of utility model

Ref document number: 7328261

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250